Gaurav Aggarwal - Aug 25, 2025 Form 4 Insider Report for Unicycive Therapeutics, Inc. (UNCY)

Role
Director
Signature
/s/ Gaurav Aggarwal
Stock symbol
UNCY
Transactions as of
Aug 25, 2025
Transactions value $
-$3,199,210
Form type
4
Date filed
8/26/2025, 05:06 PM
Previous filing
Jul 30, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aggarwal Gaurav Director C/O UNICYCIVE THERAPEUTICS, INC., 4300 EL CAMINO REAL SUITE 210, LOS ALTOS /s/ Gaurav Aggarwal 2025-08-26 0001551965

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UNCY Common Stock Conversion of derivative security +653K +57.42% 1.79M Aug 25, 2025 By Vivo Opportunity Fund Holdings L.P. F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UNCY Series A-2 Prime Preferred Stock Disposed to Issuer -$3.2M -3.2K -100% $1,000.00 0 Aug 25, 2025 Common Stock 653K $4.90 By Vivo Opportunity Fund Holdings L.P. F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $4.90, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024.
F2 Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F3 The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date.